Objective: Certain medications used in cardiovascular therapeutics may contribute to the etiology ofsubstanceinduced mood disorders. These medications include digoxin, angiotensin converting enzyme (ACE) inhibitors, f3-blockers. and calcium channel blockers. The objective ofthis study was to evaluate associations between these drugs and clinical diagnoses ofdepressive disorders in a population ofhospitalized patients.
calcium channel blockers. The most notorious neuropsychiatric complication of digoxin is delirium. Several reports, however, have also implicated digoxin in causing depression. One population-based survey of elderly subjects reported elevated mean depressive symptom scores among subjects taking digoxin (1). One prospective study of postmyocardial infarction patients (2) determined that exposure to digoxin was a statistically significant predictor ofdepressive disorders at 3 to 4 months postmyocardial infarction. Patterson (3) described a case in which a severe depressive episode followed initiation of enalapril therapy. The episode resolved with discontinuation of the medication and recurred with a subsequent rechallenge. No empirical studies have reported associations between ACE inhibitors and depressive episodes. Myler's Side Effects ofDrugs Annual contains the statement: "the fact that enalapril can cause depression is well recognized" (4) , an assertion later repeated by Elliot (5) . These assertions are based on reports to adverse drug reaction programs, and they await confirmation by empirical studies. Numerous case reports have described the occurrence of depressive symptoms in patients treated with propranolol (6-9) and other P-blockers (10) (11) (12) (13) . A variety of clinical reference sources contain statements implicating P-blockers in causing depression (14) . This possibility has been investigated in several observational, epidemiological studies. The strongest evidence of an association is provided by 2 studies based on record linkage of health care data bases (15, 16) . Both of these studies used antidepressant prescriptions as proxy markers for the existence of clinically relevant depressive disorders. Contradictory evidence, however, has been reported in other studies (17) (18) (19) (20) (21) (22) (23) .
Nifedipine, a calcium channel blocker, has been associated with depression in a few case reports (24) (25) (26) , as has verapamil (27, 28) . There is only a single report (describing 8 spontaneous reports to an adverse drug reaction data base) associating diltiazem with depression (29) . A greater volume of evidence indicates that another calcium channel blocker, flunarizine, can cause depression (30) (31) (32) (33) (34) . Flunarizine is marketed in Canada for the prevention of migraine headaches.
Methods
This study used a case-control design. Two separate case-control studies were conducted, one for subjects with congestive heart failure, the other for subjects with hypertension. Cases and controls were selected using a case-summary data base maintained in the Health Records Department of the Calgary General Hospital for submission to the Canadian Institute for Health Information (CIHI) (35) . This data base contains a hospital identification number, the age and gender of the patient, and a listing of all discharge diagnoses coded according to ICD-9. Eligible subjects were identified by downloading lists of subjects with congestive heart failure or hypertension from the data base into 2 separate microcomputer data bases. Data were downloaded for all relevant hospital discharges between April 1990 and October 1993. Prior to the selection of cases and controls from the downloaded data, an electronic check (utilizing a data base macro) was used to eliminate subjects who had multiple appearances in the data base because of multiple admissions during the study period. When there were multiple admissions for one subject, all admissions subsequent to the first admission were excluded. The ICD-9 diagnostic data in the data base al~owed a determination of whether the subjects were diagnosed with a depressive mental disorder, and hence whether they should be included in the sample. The group-of disorders regarded as depressive disorders were: major depressive episode (single episode), major depressive episode (recurrent), bipolar disorder, depressed, neurotic depression, organic affective syndrome, drug-induced organic affective syndrome, brief reactive depression, prolonged depressive reaction, and depressive disorder not elsewhere classified. Subjects with any of these ICD~9 codings were regarded as potential cases. A determination of whether the subjects had been diagnosed with another mental disorder (ICD-9 codes 290 to 319), but not a depressive mental disorder, was also possible using the electronic data. This allowed the identification of 2 control groups in each ofthe case-control studies. First, a psychiatric control group was identified, consisting of subjects with. a mental disorder other than a depressive disorder as a discharge diagnosis. Second, a nonpsychiatric control group was selected from among the subjects not receiving any psychiatric diagnosis.
Phannacoepidemiological studies may be affected by "confounding by indication" (36) . Confounding by indication refers to bias resulting from an intermixing of the effects ofa drug with the effects of the medical condition acting as a diagnostic indication for the drug. Specifically, if subjects with medical conditions that are indications for the drugs of interest have an increased risk of depression, then confounding by indication could make subjects treated with those medications appear to have an elevated risk of depression, even in the absence of a tendency for the drug to cause depression. Restriction (a traditional epidemiological technique for the control of confounding) was used in this study to control confounding by indication. In the first case-control study, selection was restricted to subjects with congestive heart failure. This set of cases and controls was used to evaluate 2 drug classes used to treat congestive heart failure: digoxin and ACE inhibitors. In the second case-control study, the selection ofcases and controls was restricted to those with hypertension, and this data set was used to evaluate ACE inhibitors, P-blockers, and calcium channel blockers. The restriction ensured that all ofthe study groups contained only subjects with one of the conditions that the medications of interest are used to treat. Hence, even if the conditions themselves were associated with an elevated risk of depression, this elevation in risk could not distort comparisons made between the groups.
After selection of the subjects, a chart review was conducted to confinn that the data base codings (of having or not having a diagnosed depressive disorder) represented actual clinical diagnoses. The chart review also recorded the medications that each subject was taking. Since the data were collected from clinical records, it was not possible to confirm the validity of the clinical diagnose-s.
Associations between depressive diagnoses and drug exposures were evaluated using ORs, exact confidence intervals (95% CI) for the ORs, and 2-tailed Fisher's exact tests (FET). The analyses (with the exception of certain large sample Fisher's exact tests) were performed using the statistical software, "Epi Info, version 6.0" (37), a shareware program produced by the World Health Organization and the United States (US) Centers for Disease Control. Logistic regression modelling utilized a statistical package for Generalized Linear Interactive Modelling (GUM), developed by the Royal Statistical Society (38) .
Some ofthe nonpsychiatric controls may not have received any form ofpsychiatric assessment or evaluation and may not have been diagnosed or coded as having a depressive disorder despite actually having such a disorder. Potentially, such misclassification of study variables could contribute to misclassification bias. Within the epidemiological literature, methods have been described for evaluating the impact of misclassification bias. One common method is "back calculation" (39) . This approach begins with a tabulation of the observed data, which are assumed to include misclassification errors. Next, the expected error rates (for example, sensitivity and specificity) of the methods used to classify the subjects' status are estimated, or plausible assumptions about these parameters are made. The observed data from the study and the anticipated error rates are then used to calculate the actual (without any misclassification) frequencies ofstudy variables that would be expected to produce the observed data under the anticipated rates of misclassification. Since hospital records ofmedication exposures are likely to be highly accurate, the major source ofmisclassification in this study is probably the classification of case-control status. More specifically, a major concern is that some proportion ofdepressive disorders may be undetected clinically and may, therefore, not be coded properly in the hospital discharge data. The end result would be a lack of sensitivity (in other words, a sizeable false-negative rate) for recorded diagnoses of depressive disorders. To help evaluate this possibility, we developed a model adapted for this study from general back-calculation methods (39). The notation used here to describe the model is based on the traditional labelling of an epidemiological 2 x 2 contingency table, with the number of drug-exposed cases being labelled "A," the number of drug-exposed controls labelled "B," the number of non exposed cases labelled "C," and the number of nonexposed controls labelled "D." In this notation, the uppercase letters denote true status, free from misclassification. In contrast, the corresponding lowercase letters are used to designate the observed data, which include misclassification errors.
Assuming no misclassification of drug exposure, the observed data in the "a" cell consist of all depressed subjects who are drug-exposed and whose depression is detected, or: a = A(Se), where Se is the sensitivity of the diagnostic and coding process. Similarly, c = C(Se). In a study without sampling (that is, a study incorporating the entire target population), the number of observed controls would equal the actual number of nondepressed subjects plus those who are depressed but are misclassified because the diagnosis was not made or recorded so that:
is the false-negative rate. In this study, however, some of the control groups were randomly selected from a larger population of eligible controls so that not every depressed subject who was misclassified as non depressed was selected into the study's data set. Therefore, the expected number, b, can be better represented as:
sents the number ofdrug-exposed true negatives selected into the control group, and P" denotes the probability ofa misclassified case being selected into the control group. Under the assumption that the proportion of misclassified cases falling into the psychiatric and nonpsychiatric control groups resembles the overall proportions in these groups in the data set, P, is the joint probability of being classified into the specified (psychiatric or nonpsychiatric) control group and the probability of selection from that group.
Since the observed data a, b, c, and d are known, as is the probability of selection employed in the random sampling procedure, these equations can be used to determine the values of A, B, C, and D at any plausible value for the sensitivity of the diagnostic process. Consequently, a parameter reflecting the true OR (AD/BC) associated with a 2 x 2 table that would be expected to result in the observed data under the assumed misclassification rates can also be estimated.
Results

A. Case-Control Studies ofCongestive Heart Failure
During the period of time covered by the data base download (April 1990 to October 1993), there were 2076 patients discharged with a diagnosis ofcongestive heart fai lure (ICD-9 code 428). Ofthese, 73 (3.5%) received a discharge diagnosis of a depressive disorder, 308 (14.8%) received a discharge diagnosis of another mental disorder, and 1695 (81.6%) received no psychiatric diagnosis. Hospital charts were located and reviewed for 67 (91.8%) ofthe cases and for 300 (97.4%) of the psychiatric controls. Nonpsychiatric controls were selected by simple random sampling at a ratio of 4 controls per case, n = 292, and charts were successfully located for 276 (94.5%) of these subjects. The data base diagnosis of a depressive disorder was confirmed by chart review for 61 Crude associations between depressive diagnoses and digoxin exposure were not observable in the data ( Table I) .
Associations were evident between depressive diagnoses and several other purported risk factors for depressive disorders. The OR for female gender in the comparison of cases to psychiatric controls was 2.05 (95% CI, 1.12 to 3.80; P = 0.016). Based on a bimodal appearance of the age distribution of the sample, subjects were divided into 2 age categories: those under the age of 70 and those 70 or more years of age. After this stratification, younger age was significantly associated with depression in the comparison of cases with psychiatric controls: OR = 1.88 (95% CI, l.01 to 3.46; P = 0.043). Despite the absence of evidence that digoxin was associated with depressive diagnoses, other possible risk factors were associated with depressive disorders in the sample, suggesting that the study design was capable of detecting expected associations.
Because female gender was positively associated with depressive diagnoses in the comparison ofcases to psychiatric controls, the digoxin-depressive-diagnosis relationship was examined within gender strata. There was no evidence, however, of a statistically significant association in either males or females (OR = 0.17; 95% CI, 0.00 to 1.17; P = 0.082 in males and OR = 0.82; 95% CI, 0.31 to 2.02; P = 0.834 in females). Hence there was no evidence that other risk factors were obscuring (through confounding) associations between digoxin and depressive disorders. ACE inhibitors are a contemporary alternative to digoxin in the treatment of congestive heart failure. For this reason, the frequency of exposure to these medications was also compared in the cases and controls using the congestive heart failure data. There was a crude association between exposure to ACE inhibitors and depressive diagnoses when the cases were compared with psychiatric controls: OR = 1.97; 95% CI, 1.03 to 3.68; P = 0.037. The strength ofassociation appeared, however, to depend on (interact with) age. In subjects aged under 65 years, the association was not evident (OR = 0.93; 95% CI, 0.14 to 4.57; P = 1.0), whereas in subjects aged over 65 years, the OR was elevated at 2.38 (95% CI, 1.15 to 4.80; P = 0.016). There was also evidence of interaction between drug exposure and gender, with the stronger association occurring in females (OR = 2.28; 95% CI, 0.98 to 5.21; P = 0.040) as compared with males (OR = 1.35; 95% CI, 0.40 to 3.95; P = 0.589). The crude association between ACE inhibitors and clinical depressive diagnoses in the subjects with congestive heart failure is displayed in Table II . An elevated OR is also seen in the comparison of cases and nonpsychiatric controls, although the association does not attain statistical significance in that comparison.
In view of the nature of the association observed between ACE inhibitors and depressive disorders in the comparison of cases and psychiatric controls (stronger in the older age group and in females), a stratified analysis was conducted for the comparison of cases and nonpsychiatric controls. Again, the association was evident only in subjects aged over 65: OR = 2.0 (95% CI, 0.97 to 4.04; P = 0.048) and not in subjects aged less than 65: OR = 0.75 (95% CI, 0.12 to 3.40; P = 1.0). Also, the association was stronger in females (OR = 2.42; 95% CI, 1.05 to 5.46; P = 0.024) than in males (OR = 0.88; 95% CI, 0.26 to 2.59; P = 1.0). Hence, in subjects with congestive heart failure, a consistent pattern of association between ACE inhibitor exposure and clinically diagnosed depressive disorders was observed; the association was strongest in females and in subjects over the age of 65. Because the stratified analysis identified an association with ACE inhibitors and possible interactions with age and gender, a multiple regression model was generated to help evaluate the statistical significance of the interactions. The psychiatric control group was used in this part ofthe analysis. An omnibus test was performed to evaluate the difference in deviance between 1) a saturated model containing indicator variables for exposure to ACE inhibitors, gender, and age (stratified at 65 years) along with all possible interaction terms and 2) a simple, multiplicative model containing only the indicator variables with no interaction terms. The change in deviance between these 2 models was 5.577, a nonsignificant change (X 2 on 4 df, P = 0.233). Hence the interactions suggested by the stratified analysis, although large enough to be clinically significant if they are legitimate, did not attain statistical significance.
B. Case-Control Studies ofSubjects with Hypertension
The initial download of electronic data identified 5136 subjects who were discharged with a diagnosis of hypertension (ICD-9 codes 401 to 405). Of these, 1127 (21.9%) received a diagnosis ofa mental disorder, 252 (4.9%) ofthese receiving a discharge diagnosis of a depressive disorder. Charts for the subjects in the latter group were identified in 245 (97.2%) instances. The chart review found confirmatory evidence of a clinically diagnosed depressive disorder in 226 (92.2%) of the cases whose charts could be located. Control subjects were selected by random sampling, at a 1 to 1 ratio for a psychiatric and nonpsychiatric control group. Of 252 psychiatric controls, charts were located for 247 (98%), and the nonpsychiatric control status was confirmed by chart review for 234 subjects (94.7%). Of252 nonpsychiatric controls, 243 charts were located (96.4%), and the diagnostic status on chart review was confirmed for 237 ofthese subjects (97.5%). Thus the total sample size for this component ofthe study was 697.
The mean age of these subjects was younger than that of the subjects with congestive heart failure at 65.7 years. When the sample was stratified into 2 categories, those aged less than 65 or those aged 65 or more, age was not associated with clinical depressive diagnoses: OR (comparison of cases to psychiatric controls) = 1.18; 95% CI, 0.80 to 1.74; P = 0.397. Gender was strongly associated with clinical depressive diag-noses irrespective of the control group used in the comparison. In the comparison of cases to psychiatric controls, the OR for female gender was 2.58 (95% CI, 1.74 to 3.85; P < 0.001). Similarly, in the comparison of cases against nonpsychiatric controls, the OR for female gender was 2.14 (95% CI, 1.45to 3.16; P = 0.002). Crude associations between case-control status and exposure to the 3 drug classes of primary interest are displayed in Tables III, IV, and V. Only the ACE inhibitors were significantly and positively associated (in the crude analysis) with depressive diagnoses.
In the congestive heart failure data, the association ofACE inhibitor exposure with depressive symptoms was stronger in females than in males, and stronger in the age group 65 years and over. A similar pattern was observed in the hypertensive subjects. In the comparison between cases and psychiatric controls, the OR for ACE inhibitors was 1.12 in males (95% CI, 0.56 t02.21; P = 0.747) and 2.12 in females (95% CI, 1.15 to 4.01; P = 0.012). In subjects under the age of 65, the OR was 1.08 (95% CI, 0.54 to 2.15; P = 0.872), whereas in subjects 65 years of age or over, the OR was 2.01 (95% CI, 1.14 to 3.55; P = 0.011). In the comparison of cases with nonpsychiatric controls, the OR for ACE inhibitors was 0.93 in males (95% CI, 0.46 to 1.85; P = 0.871) and 1.51 in females (95% CI, 0.87 to 2.63; P = 0.122). In subjects under the age of 65, the OR was 0.88 (95% CI, 0.45 to 1.69: P = 0.756), whereas in the 65 or older group, the OR was 1.60 (95% CI, 0.92 to 2.78; P = 0.087). ACE inhibitors were associated with depressive disorders, therefore, and the associations were stronger in females and in more elderly subjects.
Because the stratified analysis identified an association with ACE inhibitors and possible interactions with age and gender, a multiple regression model was generated to help evaluate the statistical significance of these apparent interactions. The psychiatric control group was used in this part of the analysis. The statistical test was performed as previously described (for the congestive heart failure data), and the result was again nonsignificant (X 2 = 5.505, df 4, P = 0.239). Thus the interactions suggested by the stratified analysis did not attain statistical significance in the logistic regression analysis. 
C. Impact ofMisclassification Bias
Application of the modelling procedure for misclassification bias suggested that the ORs observed in the analyses would not be severely affected even if a sizeable proportion of cases were being missed clinically. For example, in the evaluation of ACE inhibitor exposure in the hypertensive subjects (cases and psychiatric controls), the observed data, denoted as described previously were a = 75, b = 57, c = 151, and d = 177, leading to an observed OR of 1.54. The probability of selection of a psychiatric control subject (P,) was estimated as ajoint probability (see Method), P, = 0.052.
When the sensitivity of the process leading to a clinical diagnosis ofa depressive disorder was set at 25%, the true OR expected to produce the observed data was 1.68, only slightly higher than the OR calculated directly from the data (1.54). In this scenario, the observed number of drug-exposed cases would represent only 25% of the actual number of drugexposed cases in the target population. The expectation for the actual number in the target population would, therefore, be 4 times the observed number 75, that is, 300. The remaining 225 drug-exposed and depressed subjects would have appeared among the 4884 eligible controls. The model suggests that approximately II ofthese subjects would appear in the data set as psychiatric controls. Similarly, at this level of sensitivity, the model suggests that approximately 23 nondrug-exposed misclassified cases would have appeared as psychiatric controls. Estimates using other values for sensitivity differed even less from the observed OR: 1.58 and 1.55 at sensitivities of 50% and 75%, respectively. Thus, while it is likely that many cases of depressive disorders were not recorded in the data set, this factor alone would not appear to have a major impact on the estimates of association.
Discussion
These case-control studies did not identify associations between clinically diagnosed depressive disorders and digoxin, P-blocker, or calcium channel blocker exposure. Nevertheless, associations between ACE inhibitors and clinical diagnoses of depressive disorders were observed both in subjects with congestive heart failure and in subjects with hypertension. Furthermore, within each ofthese 2 groups, the odds of exposure among cases was compared with the odds of exposure in 2 groups of control subjects (psychiatric and nonpsychiatric controls). In this manner, 4 estimates of association were made, and each of the 4 estimated ORs was greater than one. The finding of an elevated OR was, therefore, consistently observed in the study.
The study has several limitations, including the use of existing data rather than research instruments. The diagnostic and drug exposure data are, therefore, subject to inaccuracy which, in epidemiological terms, could introduce misclassification bias. Because nondifferential misclassification of exposure status generally results in a dilution of observed effects (39) , this form of bias may account for the negative findings for digoxin, P-blockers, and calcium channel block- ers, but not for the association observed with ACE inhibitors. Additional analysis suggested that misclassification of diagnostic status would not be expected to have a major impact on the fmdings.
Case-control studies using clinical subjects are also vulnerable to selection bias. If admission to hospital was influenced both by the presence of a depressive disorder and by drug exposures, then selection bias could occur. For example, if depression increases the chance of hospitalization to a greater extent in subjects who are taking ACE inhibitors than in subjects who are not, selection bias could lead to an overestimation of the association in a case-control study using hospitalized subjects. Such effects (often called "Berkson's Bias") are not entirely implausible, but would be expected to occur with other drugs as well as with the ACE inhibitors; the latter association was not observed, however.
The study design was not capable of determining whether the depressive disorders preceded or followed exposure to ACE inhibitors. Given the clinical belief that these drugs are less likely to cause depression than some other antihypertensives, it is possible that some subjects were switched to ACE inhibitors because they were depressed. A prospective study is required to evaluate this possibility.
Numerous other variables may be risk factors for depression among medical patients. If some of these other risk factors are also associated with exposure to the drugs evaluated in this study, then confounding bias may have occurred. Studies using existing data sources typically have little opportunity to evaluate or control for the effects of confounding bias. Uncontrolled confounding, therefore, is a possible source of bias.
Although an association has been suspected, no previous epidemiological studies have identified associations between ACE inhibitors and depressive disorders. Future investigations, perhaps using other study designs, will be necessary to determine whether the association reported here is a causal one.
Clinical Implications
• ACE inhibitors may be associated with depressive disorders.
• The association between ACE inhibitors and depressive disorders is most evident in women and elderly subjects.
• The associationmay not be causal, and it requires confirmation by additional studies.
Limitations
• This study relied on existing clinical and administrative data sources, rather than research instruments.
• The study design was unable to account for several potential confounding variables.
• Temporal relationships could not be confirmed: some cases of depression may have preceded drug exposure.
